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Abstract
Background: The N-methyl-D-aspartate (NMDA) receptors play a role in behavioral abnormalities observed after
administration of the psychostimulant, methamphetamine (METH). Serine racemase (SRR) is an enzyme which synthesizes
D-serine, an endogenous co-agonist of NMDA receptors. Using Srr knock-out (KO) mice, we investigated the role of SRR on
METH-induced behavioral abnormalities in mice.
Methodology/Principal Findings: Evaluations of behavior in acute hyperlocomotion, behavioral sensitization, and
conditioned place preference (CPP) were performed. The role of SRR on the release of dopamine (DA) in the nucleus
accumbens after administration of METH was examined using in vivo microdialysis technique. Additionally, phosphorylation
levels of ERK1/2 proteins in the striatum, frontal cortex and hippocampus were examined using Western blot analysis. Acute
hyperlocomotion after a single administration of METH (3 mg/kg) was comparable between wild-type (WT) and Srr-KO mice.
However, repeated administration of METH (3 mg/kg/day, once daily for 5 days) resulted in behavioral sensitization in WT,
but not Srr-KO mice. Pretreatment with D-serine (900 mg/kg, 30 min prior to each METH treatment) did not affect the
development of behavioral sensitization after repeated METH administration. In the CPP paradigm, METH-induced
rewarding effects were demonstrable in both WT and Srr-KO mice. In vivo microdialysis study showed that METH (1 mg/kg)-
induced DA release in the nucleus accumbens of Srr-KO mice previously treated with METH was significantly lower than that
of the WT mice previously treated with METH. Interestingly, a single administration of METH (3 mg/kg) significantly
increased the phosphorylation status of ERK1/2 in the striatum of WT, but not Srr-KO mice.
Conclusions/Significance: These findings suggest first, that SRR plays a role in the development of behavioral sensitization
in mice after repeated administration of METH, and second that phosphorylation of ERK1/2 by METH may contribute to the
development of this sensitization as seen in WT but not Srr-KO mice.
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Introduction
Abuse of the psychostimulant methamphetamine (METH) is a
serious and growing worldwide problem. Long-term use of METH
results in addiction, which is characterized by compulsive drug-
seeking and drug use, with accompanying functional and
molecular changes in the brain. Addiction to METH is also a
major public health concern, since chronic use is associated with
major medical, psychiatric, cognitive, socioeconomic and legal
consequence [1,2]. Repeated consumption of METH can induce a
psychotic state (METH psychosis), with symptoms resembling
those of paranoid-type schizophrenia [3–5]. There is currently no
standard pharmacological treatment for the wide range of
symptoms associated with METH abuse [1,6,7]. Moreover, the
precise molecular and cellular mechanisms underlying the long-
term effects of METH in the brain, remain undetermined [1,8,9].
METH causes neurochemical changes in several areas of the
brain via the dopaminergic system, and consequently via
glutamatergic neurotransmission [10–13]. Repeated administra-
tion of this psychostimulant to rodents, produces long-term
behavioral changes, including behavioral sensitization and depen-
dence [14,15]. The N-methyl-D-aspartate (NMDA) receptor
antagonist MK-801 blocks the development of METH (or
amphetamine)-induced behavioral sensitization [16–20]. It is
therefore likely that the NMDA receptor plays a role in the
mechanisms of behavioral sensitization seen in rodents after
repeated administration of psychostimulants, such as METH and
amphetamine.
D-Serine is an endogenous co-agonist at the glycine-binding site
of the NMDA receptor subunit, GluN1 [21–23]. D-Serine is
synthesized from L-serine by the enzyme, serine racemase (SRR),
and shows a similar localization within the brain to D-serine
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35494[24,25]. Studies using Srr knockout (Srr-KO) mice show that SRR
is predominantly localized to forebrain neurons [26] and that
levels of D-serine in the forebrain are 10–20% of wild-type (WT)
mice [27–29], suggesting that SSR provides the main catalysis for
D-serine production in the forebrain. In addition, we reported that
NMDA-induced neurotoxicity is significantly attenuated in the
brains of Srr-KO mice, suggesting that D-serine controls the extent
of NMDA receptor-mediated neurotoxic insults [27]. It is
therefore likely that D-serine produced by SSR, plays an
important role in NMDA receptor-mediated neurotransmission
in the brain.
To study the role of SRR in METH-induced behavioral
abnormalities, we evaluated behavioral performances in acute
hyperlocomotion, development of behavioral sensitization, and
conditioned place preference (CPP) in WT and Srr-KO mice, after
the administration of METH. Furthermore, we examined the role
of SRR on the dopamine (DA) release in the nucleus accumbens
after administration of METH using in vivo microdialysis
technique. In addition, we examined whether METH adminis-
tration altered phosphorylation levels of ERK1/2 in the striatum,
since ERK1/2 phosphorylation contributes to the development of
behavioral sensitization by psychostimulants [30,31].
Results
METH-induced acute hyperlocomotion
A single dose of METH (3 mg/kg, s.c.), but not METH (1 mg/
kg, s.c.), markedly increased locomotion in both WT and Srr-KO
mice. Two-way ANOVA analysis revealed significant drug
treatment effects for METH-induced locomotor responses [geno-
type: F (1,48)=1.12, p=0.29; drug treatment: F (2,48)=26.97,
p,0.001], with no genotype x drug treatment interaction (F
(2,48)=0.27, p=0.77). Subsequent one-way ANOVA followed
post hoc Bonferroni/Dun test indicated that METH (3 mg/kg)
significantly increased locomotion in both WT and Srr-KO mice
(WT: p=0.002; Srr-KO: p,0.001 as compared to saline treated
group) (Figure 1).
Next, we examined whether pretreatment with D-serine
affected METH-induced acute hyperlocomotion in mice. Thirty
minutes after a single oral dose of D-serine (900 mg/kg) or
vehicle (10 ml/kg), mice were given a s.c dose of METH (3 mg/
kg). Two-way ANOVA analysis revealed that D-serine had no
significant effect on METH-induced acute hyperlocomotion
[genotype: F (1,24)=6.00, p=0.02; drug treatment: F
(1,24)=0.02, p=0.88; interaction: F(1,24)=0.02, p=0.89]. Stu-
dent’s t-test indicated that pretreatment with D-serine (900 mg/
kg) had no effect on METH-induced hyperlocomotion in either
WT or Srr-KO mice (WT: t=0.26, p=0.80; Srr-KO: t=0.006,
p=1.00) (Figure S1).
METH-induced behavioral sensitization
Two-way ANOVA analysis revealed a significant effect for
METH-induced hyperlocomotion [genotype: F (1,34)=7.97,
p=0.008; drug treatment: F (1,34)=33.46, p,0.001; interaction:
F (1,34)=11.83, p=0.002]. One-way ANOVA revealed a
significant (F (3,34)=18.37, p,0.001) difference among the four
groups. Challenging mice with a low dose of METH (1 mg/kg)
significantly (p,0.001) increased METH -induced hyperlocomo-
tion in WT mice previously treated with METH (3 mg/kg/day
over 5 consecutive days), compared with saline treated WT mice
(Figure 2). In contrast, METH (1 mg/kg) -induced hyperlocomo-
tion was comparable between Srr-KO mice previously treated with
METH (3 mg/kg/day over 5 consecutive days) or saline
(Figure 2), indicating a lack of METH-induced behavioral
sensitization in Srr-KO mice. Furthermore, locomotion in WT
mice pretreated with METH (3 mg/kg/day for 5 consecutive
days) was significantly (p=0.001) higher than seen in Srr-KO mice
pretreated with METH (Figure 2). These results indicated that
behavioral sensitization occurred in WT but not Srr-KO mice after
repeated administration of METH.
Figure 1. METH-induced acute hyperlocomotion in WT and Srr-KO mice. METH (1 or 3 mg/kg) or vehicle (saline; 10 ml/kg) was administered
s.c. to WT and Srr-KO mice. Behavior (locomotion) was evaluated as described in the Methods and Materials. Each value is the mean 6 SEM (n=8–10
per group). **p,0.01, ***p,0.001 as compared with the vehicle treated group.
doi:10.1371/journal.pone.0035494.g001
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METH-induced behavioral sensitization in Srr-KO mice, mice
were administered a single oral dose of D-serine (900 mg/kg/day)
or vehicle (10 ml/kg/day) thirty minutes before dosing with
METH (3 mg/kg/day). Two-way ANOVA analysis revealed a
significant genotypic effect for METH-induced locomotion
[genotype: F (1,24)=27.17, p,0.001; drug treatment: F
(1,24)=1.31, p=0.26], with no genotype x drug interaction (F
(1,24)=0.21, p=0.65). One-way ANOVA revealed significant (F
(3,24)=9.562, p,0.001) differences among the four groups.
Pretreatment with D-serine (900 mg/kg) showed no effect on
METH (1 mg/kg)-induced locomotion in either WT or Srr-KO
mice. In contrast, locomotion in WT mice pretreated with vehicle
followed by METH (3 mg/kg) was significantly (p=0.015) higher
than in Srr-KO mice treated in the same way (Figure S2),
consistent with results in Figure 2. Furthermore, locomotion in
WT mice pretreated with D-serine (900 mg/kg) followed by a
larger dose of METH (3 mg/kg) was significantly (p=0.003)
higher than in Srr-KO mice treated in the same manner (Figure
S2). These results showed that pretreatment of D-serine (900 mg/
kg) prior to each METH injection had no effect on METH (1 mg/
kg)-induced locomotion in WT and Srr-KO mice pretreated with
METH.
METH-induced DA release in the nucleus accumbens
To explore how SRR contributes to METH-induced sensitiza-
tion, we measured extracellular DA levels in the nucleus
accumbens after administration of METH (1 mg/kg), using an
in vivo microdialysis technique. A dose of METH (1 mg/kg, s.c.)
caused a marked increase in extracellular DA levels in the nucleus
accumbens of WT, not Srr-KO, mice previously treated with
METH (3 mg/kg/day over 5 consecutive days) (Figure 3).
Repeated ANOVA analysis showed a significant difference
between two groups (Time6Group, F=3.456, p=0.042). The
METH-induced DA release in the nucleus accumbes of Srr-KO
mice previously treated with METH was significantly lower than
that of WT mice previously treated with METH (Figure 3).
These findings suggest that an administration of METH (1 mg/kg)
failed to induce DA release in the nucleus accumbens of Srr-KO
mice previously treated with METH.
METH-induced rewarding effects
Mice that had only received METH spent significantly more
time in the METH assigned compartment relative to the saline
treatment compartment. The mice conditioned with saline did not
show a preference for either compartment on the CPP test day.
These data showed that a single pairing with METH (1 mg/kg,
s.c.)-induced CPP when mice were tested 24 h after conditioning.
Two-way ANOVA analysis revealed a significant drug treatment
effect for the METH-induced CPP score [genotype: F
(1,40)=0.37, p=0.55; drug treatment: F (1,40)=23.11,
p,0.001], with no genotype x drug treatment interaction
(F(1,40)=0.44, p=0.51). Student’s t-test indicated that repeated
administration of METH (1 mg/kg) significantly increased CPP
scores in both WT and Srr-KO mice (WT: t=3.71, p=0.001; Srr-
KO: t=3.07, p=0.006) (Figure 4). The data indicated that
METH treatment induced rewarding effects in both WT mice and
Srr-KO mice.
Phosphorylation of ERK1/2
ERK, a component of the mitogen-activated protein kinase
(MAPK) intracellular signaling pathway, interacts with both
dopamine and NMDA receptors in the brain. It has been reported
that the phosphorylation of ERK1/2 plays a role in behavioral
sensitization, after repeated administration of psychostimulants
[30,31]. This study examined whether phosphorylation levels of
ERK1/2 in the striatum of Srr-KO mice differed from that of WT
mice. Two-way ANOVA analysis revealed a significant effect for
METH-induced phosphorylation of ERK1/2 between WT and
Srr-KO mice [ERK1; genotype: F (1,20)=0.07, p=0.80; drug
treatment: F (1,20)=2.12, p=0.16; interaction: F (1,20)=6.13,
p=0.02; ERK2; genotype: F (1,20)=0.16, p=0.70; drug
treatment: F (1,20)=0.75, p=0.40; interaction: F (1,20)=12.89,
p=0.002]. Student’s t-test indicated that a single dose of METH
(3 mg/kg) significantly increased the phosphorylation of ERK1/2
in the WT mice [ERK1; WT: t=2.61, p=0.03; ERK2; WT:
Figure 2. The development of behavioral sensitization in mice after repeated administration of METH. Mice were treated daily for 5
consecutive days with vehicle (10 ml/kg) or METH (3 mg/kg). Seven days after the final dosing, mice were given a lower dose of METH (1 mg/kg, s.c.).
Locomotion in mice was evaluated as described in the Methods and Materials. Each value is the mean 6 SEM (n=9 or 10 per group). **p,0.01,
***p,0.001 as compared with the vehicle treated group (Bonferroni/Dunn method).
doi:10.1371/journal.pone.0035494.g002
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METH (3 mg/kg) did not increase phosphorylation of ERK1/2 in
Srr-KO mice (ERK1; Srr-KO: t=0.78, p=0.46; ERK2; Srr-KO:
t=1.79, p=0.10) (Figure 5).
In the hippocampus, two-way ANOVA analysis revealed no
significant effect for METH-induced phosphorylation of ERK1/2
between WT and Srr-KO mice [ERK1; genotype: F (1,20)=0.42,
p=0.53; drug treatment: F (1,20)=0.23, p=0.64; interaction: F
(1,20)=2.54, p=0.13; ERK2; genotype: F (1,20)=7.23, p=0.01;
drug treatment: F (1,20)=1.61, p=0.21; interaction: F
(1,20)=0.41, p=0.53](Figure S3). In the frontal cortex, the
phosphorylation of ERK1/2 was not detected between WT and
Srr-KO mice (data not shown).
Discussion
The major findings of this study are that repeated administra-
tion of METH (3 mg/kg/day for 5 days) induced behavioral
Figure 3. The effects of SRR on METH-induced increase of extracellular DA levels. A dose of METH (1.0 mg/kg, s.c) was injected into mice.
The dialysate was collected in 30-min fractions, and DA levels were measured by HPLC. Basal extracellular DA levels in the nucleus accumbens were
3.84160.301 nmol/L (n=12, mean 6 SEM). The values are the mean 6 SEM of 6 mice. *p,0.05, **p,0.01 as compared with the METH (1 mg/kg)
treated WT group (Student’s t-test).
doi:10.1371/journal.pone.0035494.g003
Figure 4. METH-induced conditioned place preference (CPP) in mice. On days 4, 6, and 8, mice were treated with vehicle (10 ml/kg) or METH
(1 mg/kg), and then confined in either a transparent or black compartment for 30 min. On days 5, 7, and 9, mice were given saline and placed in the
non- METH assigned compartment for 30 min. On day 10, the postconditioning test was performed as described in the Methods and Materials. Each
value is the mean 6 SEM (n=11 per group). **p,0.01 as compared with the vehicle treated group (Student’s t-test).
doi:10.1371/journal.pone.0035494.g004
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dose of METH (3 mg/kg) produced the same changes in acute
hyperlocomotion between Srr-KO and WT mice. From in vivo
microdialysis, we found that METH-induced DA release in the
nucleus accumbens of Srr-KO mice previously treated with
METH (3 mg/kg/day over 5 consecutive days) was significantly
attenuated as compared with WT mice previously treated with
METH (3 mg/kg/day over 5 consecutive days). To our
knowledge, this is the first report demonstrating the role of SRR
in the development of METH-induced behavioral sensitization.
Previously, we reported that levels of D-serine in the forebrain of
Srr-KO mice were reduced to approximately 10–20% of those
found in WT mice [27,29]. However, pretreatment with D-serine
(900 mg/kg) did not alter hyperlocomotion in WT and Srr-KO
mice after a single dose of METH (3 mg/kg), suggesting that
decreased levels of D-serine in the brain do not affect METH-
induced, acute hyperlocomotion in mice. Furthermore, pretreat-
ment with D-serine (900 mg/kg/day) prior to each METH
injection, failed to induce behavioral sensitization in Srr-KO mice.
It is therefore unlikely that pretreatment with D-serine affects
METH-induced behavioral abnormalities in either WT or Srr-KO
mice. These findings suggest that SRR plays an important role in
the development of behavioral sensitization in mice, following
repeated METH administration.
Behavioral sensitization following the repeated administration of
psychostimulants, including METH, is one manifestation of
sensitization in the brain. The initiation of behavioral sensitization
to psychostimulants is operationally defined as the transient
sequence of cellular and molecular events precipitated by repeated
administration of psychostimulants that leads to the enduring
changes in neural function responsible for behavioral augmenta-
tion [14,15,32,33]. The increase in extracellular DA is augmented
in the nucleus accumbens and striatum following the repeated
administration of psychostimulants. Together, the enhanced
release of DA in the nucleus accumbens plays a role in the
augmentation of behavior in the sensitized animals [14,15,32,33].
In this study, we found that Srr-KO mice pretreated with METH
did not show the release of DA in the nucleus accumbens and
behavioral augmentation after a challenge of METH, indicating a
role of Srr in the development of behavioral sensitization after
repeated administration of METH.
Accumulating evidence suggests that intracellular signaling
pathways, including that of ERK1/2 play contributes greatly to
the molecular pathophysiology of drug addiction [34–38]. Abused
drugs including amphetamine and cocaine has been shown to
activate ERK in a subset of medium-sized spiny neurons of the
dorsal striatum and nucleus accumbens, through the combined
action of NMDA and DA D1 receptors [39–41]. Pretreatment
with SL327 (30 mg/kg), a selective brain-penetrating inhibitor
of MAP-kinase/ERK kinase, blocks the development of behav-
ioral sensitization after repeated amphetamine treatment [39],
suggesting a role for this pathway in long-lasting behavioral
sensitization by psychostimulants. It has also been shown that
phosphorylation of ERK1/2 in the striatum increases after
administration of psychostimulants [30,31,40–41]. In this study,
a single dose of METH (3 mg/kg) significantly increased the
phosphorylation of ERK1/2 in the striatum of WT, but not Srr-
KO mice. This suggests that phosphorylation of ERK1/2 in the
striatum following a single dose of METH, is at least in part,
mediated by SRR, although the precise mechanisms are currently
unclear. Previously, we reported that NMDA-induced neurotox-
icity is significantly attenuated in the brains of Srr-KO mice,
suggesting that D-serine controls the extent of NMDA receptor-
mediated neurotoxic insults [27]. It is likely that the lack of
behavioral sensitization seen in Srr-KO mice may be the result of
decreased DA release and ERK1/2 phosphorylation, due to
NMDA receptor hypofunction, although this will need to be
investigated further.
Figure 5. Phosphorylation of ERK1/2 in the striatum after a single dose of METH. Mice were sacrificed 15 minutes after a single dose of
either METH (3 mg/kg, s.c.) or vehicle (10 ml/kg, s.c.). Western blot analysis of phospho-ERK1/2 and total ERK1/2 protein was performed as described
in the Methods and Materials. Values are the mean 6 S.E.M. (n=6 per group). *p,0.05, **p,0.01 as compared with the vehicle treated group
(Student’s t-test).
doi:10.1371/journal.pone.0035494.g005
Serine Racemase and Methamphetamine Sensitization
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35494The CPP paradigm is a widely used animal model on the
rewarding effects of drugs [42]. The NMDA receptor antagonist
MK-801 fails to block amphetamine-induced place preference in
rats, suggesting that NMDA receptors may not be involved in the
rewarding effects of psychostimulants [43]. Miyamoto et al. [44]
reported that mice with mutant GluN2A, one of four GluN2
subunits (GluN2A-D) of the NMDA receptor, developed METH-
induced place preference to the same degree as WT mice, whereas
behavioral sensitization was significantly reduced in these mutants
compared with WT mice. This suggests that the GluN2A subunit
may play a role in the development of behavioral sensitization, but
not rewarding effects, in mice repeated exposure to METH. In this
study, Srr-KO mice developed METH-induced place preference to
the same degree as WT mice. It is therefore unlikely that NMDA
receptors play a major role in the development of METH-induced
rewarding effects in mice.
Along with D-serine, glycine is also a co-agonist at the glycine
modulatory site of the NMDA receptor [21]. We reported that
brain derived levels of glycine and other amino acids, including,
glutamate and glutamine, were comparable between WT and Srr-
KO mice [27,29], suggesting that glycine may not compensate for
decreased D-serine levels in the brains of Srr-KO mice. In
addition, forebrain levels of the NMDA subunits, GluN2A,
GluN2B, and GluN1 were comparable between WT and Srr-
KO mice [27]. No difference was found in [
3H](+)-MK-801
binding between brain regions (frontal cortex, hippocampus,
striatum, cerebellum) from WT and Srr-KO mice (Table S1). It
would seem that the expression of NMDA receptors is comparable
between WT and Srr-KO mice. It is highly probable that the
reduced D-serine in the forebrain of Srr-KO mice may, in part,
contribute to the lack of METH-induced behavioral sensitization,
although this too needs to be examined in further studies.
In conclusion, this study has pointed to a role for SRR in the
development of behavioral sensitization, but not rewarding effects,
in mice that have been repeatedly exposed to METH. It also
suggests that decreased DA release in the nucleus accumbens and
decreased phosphorylation of the ERK1/2 protein may contribute
to the lack of METH-induced behavioral sensitization in Srr-KO
mice.
Materials and Methods
Animals
Srr-KO mice were generated from C57BL/6- derived embry-
onic stem cells transfected with a gene-targeting vector containing
C57BL/6 mouse genomic DNA, and the colony was expanded by
crossing with C57BL/6 mice [26]. The generation and genotyping
of Srr-KO and WT mice with a pure C57BL/6 genetic
background has been reported previously [26]. WT and Srr-KO
mice aged 2–3 months were used for all behavioral studies. The
mice were housed in clear polycarbonate cages
(22.5633.8614.0 cm) in groups of 5 or 6 per cage, under a
controlled 12/12-h light–dark cycle (lights on from 7:00 AM to
7:00 PM), with a room temperature of 2361uC and humidity at
5565%. The mice were given free access to water and food
pellets. The experimental procedure (Permit Number: #23-151)
was approved by the Animal Care and Use Committee of Chiba
University.
Drug Administration
METH (D-methamphetamine hydrochloride) was purchased
from Dainippon-Sumitomo Pharmaceutical Ltd., (Osaka, Japan)
and D-serine from Sigma-Aldrich Corporation (St. Louis, MO).
METH was dissolved in physiological saline and injected
subcutaneously (s.c.). The dose of METH was expressed as a
hydrochloride salt. D-Serine dissolved in saline was administered
orally at a concentration of 900 mg/kg of body weight. Other
chemicals were purchased from commercial sources.
METH-induced Acute Hyperlocomotion
METH (1 and 3 mg/kg) or a vehicle of physiological saline
(10 ml/kg) was administered s.c. into mice. Locomotor activity
was measured using an animal movement analysis system
(SCANET SV-10, Melquest, Toyama, Japan), as reported
previously [45–47]. The system consisted of a rectangular
enclosure (4806300 mm). The side walls (height, 60 mm) of the
enclosure were equipped with 144 pairs of photosensors located
30 mm from the bottom edge and at 5 mm intervals. Recordings
were taken from single animals. A pair of photosensors was
scanned every 0.1 s to detect the animal movement. The
intersection of paired photosensors (10 mm apart) in the enclosure
was counted as one unit of locomotor activity. Data was collected
for 180 min (60 min of habituation and for 120 min after the
injection of METH or saline). To examine the role of D-serine in
METH-induced acute hyperlocomotion, animals were pretreated
with D-serine, before administration of METH. Thirty minutes
after a single oral dose of D-serine (900 mg/kg) or vehicle (10 ml/
kg), mice were administered a dose of METH (3 mg/kg, s.c).
Locomotor activity was measured using the animal movement
analysis system (SCANET SV-10, Melquest, Toyama, Japan),
described above.
METH-induced Behavioral Sensitization
Wild type and Srr-KO mice were given a single s.c. dose of
vehicle (10 ml/kg) or METH (3 mg/kg), and returned to their
home cages. This process was repeated for each animal, over 5
consecutive days. One week after the final treatment, each mouse
was given a low dose of METH (1 mg/kg, s.c.), and behavioral
changes (locomotion) were measured using the animal movement
analysis system (SCANET SV-10, Melquest, Toyama, Japan),
described above.
Next, mice were pretreated with D-serine in order to examine
its role in METH-induced behavioral sensitization. Both WT and
Srr-KO mice were treated with either: vehicle (10 ml/kg) +
METH (3 mg/kg) group or D-serine (900 mg/kg) + METH
(3 mg/kg) group. Injections were given 30 min apart. After the
administration of METH, mice were returned to their home cages
and this treatment was repeated over 5 consecutive days. One
week after the final treatment, all mice were given a low dose of
METH (1 mg/kg, s.c.), and behavioral changes (locomotion) were
measured using the animal movement analysis system (SCANET
SV-10, Melquest, Toyama, Japan), described above.
Measurement of extracellular DA levels using in vivo
microdialysis
Mice were anesthetized with sodium pentobarbital prior to the
stereotaxic implantation of a probe into the nucleus accumbens
(+1.1 mm anteroposterior, +1.0 mm mediolateral from the
bregma, and 24.0 mm dorsoventral from the dura), according
to the Franklin and Paxinos Atlas [48], as reported previously [49].
Probes were secured onto the skull using stainless-steel screws and
dental acrylic. Twenty-four hours after surgery, in vivo micro-
dialysis was performed on conscious and free moving mice. Probes
were perfused continuously with artificial CSF (147 mM NaCl,
4 mM KCl, and 2.3 mM CaCl2) at a rate of 2 ml/min. METH
(1 mg/kg, s.c.) was administered into mice. The dialysate was
collected in 30-min fractions. After in vivo microdialysis experi-
Serine Racemase and Methamphetamine Sensitization
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confirmed in all mice. The DA levels in each fraction were
measured by high performance liquid chromatography (HPLC),
with electrochemical detection using a reversed phase column
(EICOMPAK PP-ODS, 4.6630 mm, Eicom, Kyoto, Japan) and a
mobile phase 1% MeOH/100 mM phosphate buffer (pH 6.0)
including 50 mg/L disodium EDTA disodium and 500 mg/L
sodium decane-1-sulfonate.
Conditioned Place Preference (CPP)
The place conditioning paradigm (CPP; Brain Science Idea
Inc., Osaka, Japan) was used to study METH-induced rewarding
effects, as reported previously [49]. Mice were allowed to move
freely between transparent and black compartments for 15 min,
once a day, for 3 days (days 1–3), as preconditioning. On day 3,
the time spent in each compartment was measured. There was no
significant difference between time spent in the black compart-
ment with a smooth floor and the time spent in the transparent
compartment with a textured floor, indicating that mice had no
compartment preference before conditioning. On days 4, 6, and 8,
mice were administered either vehicle (10 ml/kg, s.c.) or METH
(1.0 mg/kg, s.c.), and then confined in either the transparent or
black compartment for 30 min. On days 5, 7, and 9, the mice were
given vehicle and placed in the non- METH assigned compart-
ment, for 30 min. On day 10, the post-conditioning test was
performed without drug treatment, and the time individual mice
spent in each compartment was measured for 15 min. A
counterbalanced protocol was used in order to nullify the initial
preference of each mouse. The CPP score was designated as the
time spent in the drug-conditioning sites minus the time spent in
the saline-conditioning sites.
Western Blot Analysis
In a preliminary experiment, we examined the time course for
phosphorylation of ERK1/2 in the striatum, after a single dose of
METH (3 mg/kg). We found increased phosphorylation of
ERK1/2 15 min after a single METH administration (data not
shown), consistent with a previous result [50]. In further
experiments, mice were therefore sacrificed 15 min after dosing
with either saline (10 ml/kg) or METH (3 mg/kg), then, the
striatum, frontal cortex and hippocampus were dissected out on
ice. Briefly, striatum from individual mice were frozen and
homogenized in 500 ml of lysis buffer (20 mM TBS, pH 7.6,
10 mM NaF, 1 mM Na3VO4, 1% Triton x-100, 5 mM EDTA,
5 mM EGTA containing protease inhibitor) using a Polytron
homogenizer. The sample was left to stand on ice for 30 min and
then centrifuged at 10,0006g and 4uC for 30 min. Total protein
in the supernatant was measured using the DC protein assay (Bio-
Rad, Hercules, CA). The sample was then diluted with 56SDS
sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2%
SDS, 5% b-mercaptoethanol and bromophenol blue). Aliquots
(10 mg protein) of protein were incubated for 5 min at 95uC, then
separated using SDS-PAGE on 12% polyacrylamide gels. Proteins
were transferred for 1 h onto a polyvinylidene difluoride (PVDF)
membrane (GE Healthcare Amersham Hybond
TM-P, UK), using
Trans Blot Mini Cell apparatus (Bio-Rad, Hercules, CA). The
transfer buffer consisted of 25 mM Tris and 192 mM glycine.
After protein transfer, membranes were blocked for 45 min in
TBS-T (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.1% Tween-
20) containing 5% skimmed milk at RT, followed by incubation
with anti-rabbit P44/42-ERK antibody (1:1000, Cell Signaling,
Cambridge, MA), overnight at 4uC in TBS-T, containing 5%
BSA. After three washes in TBS-T, membranes were incubated
with secondary antibody (1:15,000) in TBS-T for 1 h at RT. After
repeated washes, protein bands were detected using the ECL
chemiluminescence detection system (GE Healthcare Bioscience,
UK). Images were captured using a Fuji LAS3000-mini imaging
system (Fujifilm, Tokyo, Japan), and chemiluminescence bands
were quantified. To calculate the amount of phosphorylated
protein relative to total protein, membranes were stripped in
buffer (100 mM 2-mercaptoethanol, 2% SDS, and 62.5 mM Tris-
HCl, pH 6.7) at 60uC for 30 min, washed, blocked, re-incubated
with rabbit anti-ERK (1:1000, Cell signaling, Cambridge, MA),
and detected as described above.
Statistical Analysis
All data were expressed as a mean 6 standard error of the mean
(S.E.M.). The behavior data, CPP score and ERK expression data
were analyzed by two-way ANOVA (genotype vs. drug treatment).
Student’s t-test and one-way analysis of variance (ANOVA),
followed Bonferroni/Dunn test were used for comparison between
the two groups and comparison of multiple groups, respectively.
The results of extracellular DA levels were analyzed by repeated
one-way ANOVA, followed by the student’s t-test. Values of
p,0.05 were regarded as statistically significant.
Supporting Information
Figure S1 Effect of pretreatment with D-serine on acute
hyperlocomotion after a single dose of METH. Thirty
minutes after a single oral dose of vehicle (10 ml/kg) or D-serine
(900 mg/kg), WT and Srr-KO mice were given a dose of METH
(3 mg/kg, s.c.). Behavioral evaluation of locomotion was per-
formed 2 hours after the dose of METH, as described in the
Methods and Materials section. Each value is the mean 6 SEM
(n=7 per group). NS: Not significant (Student’s t-test).
(TIFF)
Figure S2 Effects of pretreatment with D-serine on
behavioral sensitization after repeated administration
of METH. Thirty minutes after a single oral administration
of vehicle (10 ml/kg) or D-serine (900 mg/kg), WT and Srr-KO
mice were dosed with METH (3 mg/kg) for 5 consecutive days.
Seven days after the final dose of METH, a lower dose of METH
(1 mg/kg, s.c.) was administered to all mice. Behavioral evalua-
tion of locomotion was performed. Each value is the mean 6 SEM
(n=7 per group). ***p,0.01 as compared with the vehicle treated
group (Bonferroni/Dunn method). NS: Not significant (Student’s
t-test).
(TIFF)
Figure S3 Phosphorylation of ERK1/2 in the hippocam-
pus after a single dose of METH. Mice were sacrificed
15 minutes after a single dose of either METH (3 mg/kg, s.c.) or
vehicle (10 ml/kg, s.c.). Western blot analysis of phospho-ERK1/2
and total ERK1/2 protein was performed as described in the
Methods and Materials. Values are the mean 6 S.E.M. (n=6 per
group).
(TIFF)
Table S1 [
3H](+)-MK-801 binding to mouse brain
regions. Binding of [
3H](+)-MK-801 (3 nM; 1.02 TBq/mmol,
PerkinElmer, MA, USA) to the crude membranes from brain
regions (frontal cortex, hippocampus, striatum, cerebellum) was
performed. Non-specific binding was determined in the presence
of 10 mMo f( +)-MK-801. There were no differences between WT
mice and Srr-KO mice. Values are the mean 6 S.E.M. (n=7 per
group).
(DOCX)
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